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Human and simian immunodeficiency viruses (HIV/SIVs) use CD4 as
the primary receptor to enter target cells. Here, we show that the
chimpanzee CD4 is highly polymorphic, with nine coding variants
present in wild populations, and that this diversity interferes with
SIV envelope (Env)–CD4 interactions. Testing the replication fitness
of SIVcpz strains in CD4+ T cells from captive chimpanzees, we found
that certain viruses were unable to infect cells from certain hosts.
These differences were recapitulated in CD4 transfection assays,
which revealed a strong association between CD4 genotypes and
SIVcpz infection phenotypes. The most striking differences were ob-
served for three substitutions (Q25R, Q40R, and P68T), with P68T
generating a second N-linked glycosylation site (N66) in addition to
an invariant N32 encoded by all chimpanzee CD4 alleles. In silico
modeling and site-directed mutagenesis identified charged residues
at the CD4–Env interface and clashes between CD4- and Env-encoded
glycans as mechanisms of inhibition. CD4 polymorphisms also re-
duced Env-mediated cell entry of monkey SIVs, which was dependent
on at least one D1 domain glycan. CD4 allele frequencies varied
among wild chimpanzees, with high diversity in all but the western
subspecies, which appeared to have undergone a selective sweep.
One allele was associated with lower SIVcpz prevalence rates in the
wild. These results indicate that substitutions in the D1 domain of the
chimpanzee CD4 can prevent SIV cell entry. Although some SIVcpz
strains have adapted to utilize these variants, CD4 diversity is main-
tained, protecting chimpanzees against infection with SIVcpz and
other SIVs to which they are exposed.
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Simian immunodeficiency viruses (SIVs) represent a diversegroup of lentiviruses that infect over 40 primate species in
sub-Saharan Africa (1). Most of these comprise Old World
monkeys (Cercopithecidae), but chimpanzees (Pan troglodytes)
and western gorillas (Gorilla gorilla) also harbor SIV (2–5).
Studies of antiviral restriction factors, such as APOBEC, tetherin,
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TRIM5, and SAMHD1, have suggested that SIVs have been
infecting primates for millions of years (6–8), which is consistent
with their complex evolutionary history characterized by virus–
host coevolution, cross-species transmission, recombination, and
lineage extinction (9–13). SIVs can be highly pathogenic in both
primate and human hosts (14, 15), with SIVcpz from chim-
panzee having generated HIV type 1 (HIV-1), the cause of
the AIDS pandemic (16). Primate hosts with more longstanding
SIV infections, such as African green monkeys (Chlorocebus genus)
and sooty mangabeys (Cercocebus atys), have evolved mechanisms
that shield them from the pathogenic effects of their SIV strains
(15, 17–19). However, such protective barriers are absent when
SIVs invade new, nonadapted hosts.
Chimpanzees (P. troglodytes) are comprised of four geo-
graphically distinct subspecies, including western (Pan troglodytes
verus), Nigeria-Cameroonian (Pan troglodytes ellioti), central
(Pan troglodytes troglodytes), and eastern (Pan troglodytes
schweinfurthii) chimpanzees (SI Appendix, Fig. S1). Only the
central and eastern subspecies are SIVcpz-infected (16, 20–22),
suggesting that this virus was introduced after the divergence and
geographic separation of the other two subspecies. Analysis of
the SIVcpz genome has shown that it is mosaic, indicating ac-
quisition by cross-species transmission and recombination of
SIVs infecting monkey species on which chimpanzees prey (10).
Central chimpanzees subsequently transmitted SIVcpzPtt to hu-
mans, generating both pandemic (group M) and nonpandemic
(group N) HIV-1, as well as to western lowland gorillas (Gorilla
gorilla gorilla), generating SIVgor (5, 22, 23). Western gorillas, in
turn, transmitted SIVgor to humans, generating HIV-1 groups O
and P (24, 25). Although the impact of SIVgor infection on the
health and longevity of wild gorillas is not known, SIVcpz is
pathogenic in its natural host (26, 27). Infected chimpanzees in
Gombe National Park, Tanzania, have a higher mortality than
uninfected chimpanzees (27, 28). In addition, infected females
have lower birth rates and a higher infant mortality (27, 28). Even
members of chimpanzee subspecies that do not naturally harbor
SIVcpz are susceptible to infection and disease. Examples include
the transmission of SIVcpzPtt from a central chimpanzee to a
Nigeria-Cameroonian cage mate (29) and the experimental in-
fection of a western chimpanzee with SIVcpzPts that resulted in
high titer viremia, CD4 T cell depletion, and clinical AIDS requiring
antiretroviral therapy (30).
Despite their genetic diversity, all SIVcpz strains characterized
to date share an identical genome structure (10). This indicates
that SIVcpz arose only once, which may seem surprising, given
that chimpanzees are routinely exposed to a plethora of SIVs
through their hunting behavior (31). The absence of additional
SIV infections has been attributed to the antiviral activity of
innate restriction and viral dependency factors, such as proteins
of the APOBEC3 family and the nucleoporin RanBP2, which
represent potent barriers to cross-species transmission (7, 32).
However, these host factors cannot explain the uneven distri-
bution of SIVcpz in wild chimpanzee populations, which is
characterized by high prevalence rates in some communities and
rare or absent infection in others (4, 21, 22). It is also unclear
why Nigeria-Cameroonian chimpanzees, which are susceptible to
infection (29), do not harbor SIVcpz. Although separated from
SIVcpz-infected P. t. troglodytes apes by the Sanaga River, this
boundary is not absolute (22, 33). Chimpanzees thus appear to
have evolved additional protective mechanisms that limit their
infection with SIVcpz and other SIVs.
Unlike lentiviruses infecting other mammals, SIVs gain entry
into target cells by using CD4, which is expressed on a variety of
immune cells, including helper T cells, macrophages, and dendritic
cells. Helper T cells require CD4 to stimulate the interaction of
their T cell receptor (TCR) with major histocompatibility complex
class II (MHC II) molecules expressed on antigen-presenting cells.
As part of the TCR complex, the most outward domain of CD4
(D1 domain) interacts with a nonpolymorphic region on MHC II
(34–36). Interestingly, this same D1 domain is also the region that
is bound by the envelope (Env) glycoprotein of primate lentiviruses
(37, 38). Several groups have compared the amino acid sequences
of CD4 between different primate species and found that residues
in the D1 domain are under positive selection (39, 40). Moreover,
African green monkeys, sooty mangabeys, and chimpanzees are
known to encode polymorphic CD4 receptors (41–43). It has thus
been suggested that the CD4 diversification in the primate lineage
is the result of SIV-driven selection (40); however, evidence for this
hypothesis has been lacking. Here, we show that naturally occurring
amino acid substitutions in the D1 domain of the chimpanzee
CD4 not only curb SIVcpz infection, but potentially also guard
against cross-species transmission of SIVs infecting monkeys that
are hunted by chimpanzees.
Results
Chimpanzee CD4+ T Cell Cultures Differ in Their Susceptibility to
SIVcpz Infection. Generating infectious molecular clones (IMCs)
of SIVcpz, we previously noted that some viruses that replicated
efficiently in human CD4+ T cells were unable to infect chim-
panzee CD4+ T cells (44). To examine this surprising phenotype,
we obtained leftover blood samples from 28 healthy chimpanzees
housed at US primate centers and infected their CD4+ T cells
with a panel of eight chimpanzee viruses representing both
SIVcpzPtt (MT145, EK505, MB897, LB715, and GAB2) and
SIVcpzPts (BF1167, TAN2, and TAN13) strains (21, 44–47).
SIVcpz IMCs were transfected, normalized based on infectivity
in a permissive cell line (TZM-bl), and used to infect CD4+
T cells at a multiplicity of infection of 0.1 (Fig. 1). As observed
previously (21, 44, 47), all SIVcpz strains replicated efficiently in
human CD4+ T cells (Fig. 1A). However, their ability to establish
a productive infection in chimpanzee CD4+ T cells varied con-
siderably. Of the 28 chimpanzees tested, only 9 supported the
replication of all, or nearly all, SIVcpz strains (e.g., Melissa in
Fig. 1 B and D) while 18 others were refractory to six of the eight
viruses (e.g., Dona in Fig. 1 C and D). Although not all viruses
could be tested in cells from all animals, 15 chimpanzees sup-
ported replication of only TAN2 and MT145 while 3 others
supported replication of only EK505 and MT145 (Fig. 1D). Cells
from one chimpanzee (Chip) supported the replication of MT145,
EK505, GAB2, and LB715, but not MB897, BF1167, and TAN2
(Fig. 1D). These infectivity patterns were reproducible in all in-
stances where repeat blood samples from the same individuals
were available (SI Appendix, Table S1). Only a single SIVcpz strain,
MT145, was able to replicate in CD4+ T cells from all 28 chim-
panzees (Fig. 1D). These results showed that, unlike human CD4+
T cells, chimpanzee CD4+ T cells were refractory to a subset of
viruses, with susceptibility influenced by both host- and virus-
specific determinants.
Refractory CD4+ T Cells Exhibit an Entry Block. To determine at
which step in the life cycle SIVcpz was blocked, we generated a
replication-competent SIVcpz reporter virus by inserting an en-
hanced green fluorescent protein (eGFP) gene between the env
and nef genes of the SIVcpz MB897 molecular clone (SI Ap-
pendix, Fig. S2A). A transfection-derived stock of this reporter
virus was then used to infect activated human and chimpanzee
CD4+ T cells. Consistent with results obtained for the WT
MB897 strain (Fig. 1D), eGFP expression was detected in CD4+
T cells from humans and susceptible chimpanzees, but not in
CD4+ T cells from refractory chimpanzees (SI Appendix, Fig.
S2B). However, complementation of the MB897 reporter virus
with the vesicular stomatitis virus G protein (VSV-G) resulted
in productive infection of all cultures (SI Appendix, Fig. S2B).
These data indicated that SIVcpz was inhibited at the level of
cell entry.
CD4 Polymorphisms Govern the Susceptibility of CD4+ T Cells to
SIVcpz Infection. In addition to CD4, SIVcpz utilizes the chemo-
kine receptor CCR5 to infect target cells (21, 44). Since the
VSV-G complementation studies suggested a block at the re-
ceptor and/or coreceptor level, we sequenced the CD4 and
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CCR5 genes of all 28 chimpanzees. In contrast to the CCR5
gene, which comprises a single coding exon, the CD4 gene is
expressed from nine exons, some of which have been reported to
be polymorphic (42). Since previous studies did not ensure
linkage of variable sites and failed to guard against PCR artifacts
(42), we extracted RNA from chimpanzee CD4+ T cells and used
limiting dilution RT-PCR to amplify single CD4 transcripts (48).
These analyses showed that none of the 28 chimpanzees
exhibited mutations in their CCR5 gene. However, analysis of
their CD4 sequences revealed several single nucleotide poly-
morphisms (SNPs), four of which changed the amino acid
sequence of the mature CD4 protein (SI Appendix, Fig. S3A).
These nonsynonymous SNPs caused substitutions at positions 40
(Q/R), 52 (N/K), 55 (V/I), and 68 (P/T), the combination of
which resulted in five CD4 variants that differed solely in their
D1 domain (Fig. 1E). Importantly, the P68T substitution created
a potential N-linked glycosylation site (PNGS) at position 66, in





Fig. 1. Chimpanzee CD4+ T cells differ in their susceptibility to SIVcpz infection. (A–C) The replication potential of eight SIVcpz strains is shown in activated
CD4+ T cells from one human (A) and two chimpanzees (B and C). Viral replication was monitored in culture supernatants by determining reverse tran-
scriptase (RT) activity (ng/mL). (D) CD4+ T cells from 28 captive chimpanzees (columns) were infected with different strains of SIVcpz (rows) and monitored for
viral replication. The chimpanzee-adapted HIV-1 SG3 strain was used for positive control (SI Appendix, SI Materials and Methods). RT activity at day 13 was
used to classify each culture as supporting robust (>5 ng/mL RT, dark circles), weak (1 to 5 ng/mL RT, grey circles), or no (<1 ng/mL RT, white circles) viral
replication (SI Appendix, Table S1). Replication results are shown in relation to the respective chimpanzee CD4 genotype, with the position of polymorphic
amino acid residues highlighted. (E) Protein sequences of five chimpanzee CD4 variants shown in comparison with human CD4 (residues are numbered
according to their position in the mature CD4 protein). Extracellular (D1 to D4), transmembrane (TM), and intracytoplasmic domains of the protein are in-
dicated relative to their coding exons (highlighted by alternating black and blue text), with the D1 domain underlined in red. Dots indicate amino acid
identity to the human sequence, with the polymorphic sites in the D1 domain highlighted in red. Conserved and polymorphic potential N-linked glycosylation
sites (PNGSs) are shaded in gray and red, respectively.









all chimpanzee CD4 alleles (Fig. 1E). Based on the amino acids
present at positions 40, 52, 55, and 68, we designated the
chimpanzee CD4 alleles QNIP, QNVP, QNVT, RNVP, and
RKVT, respectively (SI Appendix, Table S2); the latter two had
not previously been described (42).
Comparing the CD4 allelic diversity between permissive and
refractory cultures, we found a remarkable association between
the CD4 genotype and SIVcpz infection phenotype (Fig. 1D).
CD4+ T cells from four chimpanzees, which were heterozygous
for the QNVT and QNVP alleles, supported replication of all
eight SIVcpz strains while CD4+ T cells from four other chim-
panzees, which were heterozygous for QNVT and QNIP alleles,
supported the same set of viruses, except for GAB2. In contrast,
chimpanzees homozygous for the QNVT allele supported in-
fection of only two of the eight SIVcpz strains. This was also true
for chimpanzees heterozygous for the QNVT and RKVT alleles
except this genotype inhibited TAN2 instead of EK505. In gen-
eral, CD4+ T cells from chimpanzees with the same CD4 genotype
were susceptible to infection by the same set of viruses while even
a single amino acid substitution in one of the two CD4 alleles
changed the number or types of viruses that were able to replicate
(Fig. 1D).
Chimpanzee Subspecies Differ in Their CD4 Diversity. The finding of
new CD4 alleles among captive chimpanzees suggested that
additional variants might exist in wild populations. To determine
the full extent of CD4 diversity, we thus made use of our ex-
tensive collection of blood and fecal samples obtained previously
from wild and sanctuary chimpanzees for molecular epidemio-
logical studies of SIVcpz and ape Plasmodium infections (22, 49,
50). Samples were selected based on their geographic and sub-
species origin, SIVcpz infection status, and individual informa-
tion (SI Appendix, Table S3). Since the chimpanzee CD4 gene
spans a 19-Kb region on chromosome 12, with a large intron
(13.7 Kb) separating exons 2 and 3, we were unable to amplify
the entire CD4 coding region from a single DNA template. How-
ever, since all CD4 polymorphisms were located in the D1 domain,
we amplified exon 2 (247 bp) and exon 3 (222 bp) separately, se-
quencing their respective amplicons without fragmentation to
maintain linkage between polymorphic sites. Homozygous loci
were amplified up to eight times to exclude allelic dropout. Using
this approach, we CD4 genotyped 60 P. t. verus, 41 P. t. ellioti,
246 P. t. troglodytes, and 197 P. t. schweinfurthii apes that were
sampled at 58 sites throughout their range (SI Appendix, Fig. S1).
Although exons 2 and 3 were sequenced separately, we were able
to infer 13 different D1 domain haplotypes from individuals who
were homozygous for one of the two exons (SI Appendix, Fig. S3B).
These haplotypes contained one synonymous SNP (g/a) at the
second nucleotide of exon 2 (nucleotide position 51 of the CD4
coding sequence) and five nonsynonymous SNPs, which resul-
ted in amino acid substitutions at positions 25, 40, 52, 55, and
68 of the mature CD4 protein. Comparison of these to CD4
sequences from other ape species identified the (g)QQNVP
allele as the ancestral state, which appeared to have diversified
both by point mutations and recombination, including within
exons 2 and 3 (SI Appendix, Fig. S3B). Thus, in contrast to the
human CD4, for which the most common D1 variant occurs at a
frequency of only 6.6 × 10−5 (SI Appendix, SI Materials and
Methods), the chimpanzee CD4 is highly polymorphic in this
domain, with nine coding variants of CD4 identified in wild pop-
ulations (Fig. 2A).
Chimpanzees are believed to have originated in west central
Africa where they initially split into two lineages when the an-
cestor of P. t. verus and P. t. ellioti diverged from the ancestor of
P. t. troglodytes and P. t schweinfurthii (51). Given these rela-
tionships and the fact that only central and eastern chimpanzees
are SIVcpz-infected, we expected P. t. verus and P. t. ellioti to
exhibit similar levels of CD4 diversity and to differ from P.
t. troglodytes and P. t. schweinfurthii both in the number and dis-
tribution of CD4 alleles. However, this was not the case. Instead,
we found P. t. ellioti and P. t. troglodytes to be most similar, with
exon 2 QQ and QR alleles and exon 3 NVP, NIP, and KVT
alleles present at comparable frequencies in both subspecies.
Although P. t. troglodytes exhibited two additional exon 3 alleles
(NVT and KVP), both were extremely rare and may thus have
been missed in the less extensively sampled P. t. ellioti subspecies.
P. t. schweinfurthii also encoded multiple CD4 alleles, but their
frequencies differed markedly from those in P. t. troglodytes and
P. t. ellioti. For example, using the CD4 exon 3 haplotype fre-
quencies, GST (a measure of population differentiation) (52)
between P. t. troglodytes and P. t. schweinfurthii was 0.31, com-
pared with only 0.11 between P. t. troglodytes and P. t. ellioti.
Moreover, none of the eastern chimpanzees encoded the
R40 allele, but instead some encoded an R25 allele, which was
found only in chimpanzees living in Gombe National Park in
Tanzania (SI Appendix, Table S3). The most surprising finding
was that P. t. verus apes did not exhibit any CD4 polymorphisms.
Although 60 individuals were sampled at five different locations
throughout West Africa (SI Appendix, Fig. S1), every single one
was homozygous for the (a)QQNVT allele (Fig. 2B). Given the
scarcity of the exon 3 NVT allele in the other three subspecies,
the predominance of this allele is unlikely the result of a founder
effect. Instead, P. t. verus apes appear to have undergone a se-
lective sweep, possibly in response to an SIV-like pathogen that
has since gone extinct. Taken together, these findings suggest
that the various CD4 polymorphisms evolved before the in-
troduction of present-day SIVcpz and likely already existed in
the chimpanzee ancestor.
CD4 Polymorphisms Inhibit SIVcpz Infection. To examine the in-
teraction of the nine CD4 alleles with individual SIVcpz Envs, we
developed a single round infection assay by transfecting 293T cells
with vectors expressing human and chimpanzee CD4 alleles, along
with the chimpanzee CCR5 gene, and then infecting these cells with
pseudotyped viruses carrying the Envs of different SIVcpz strains.
As the pseudotyping backbone, we used an env-deficient version
of the GFP-expressing MB897 reporter virus, which allowed the
use of flow cytometry to identify infected (GFP-expressing) cells
A
B
Fig. 2. Allelic diversity of CD4 in chimpanzees. (A) CD4 coding variants
identified in wild chimpanzee populations. D1 domain alleles are compared
with the human CD4, with partial exons 2 and 3 derived sequences color-
coded. Only the polymorphic region is shown (see Fig. 1E for an alignment of
full-length CD4 coding sequences). Dots indicate identical amino acids while
arrows highlight polymorphic sites, with their position in the mature CD4
protein indicated. (B) Frequencies of exon 2 and 3 alleles among members of
the four chimpanzee subspecies. Exon 2 includes polymorphic amino acids at
positions 25 (Q/R) and 40 (Q/R) while exon 3 includes polymorphic amino
acids at positions 52 (N/K)), 55 (I/V), and 68 (P/T). The number of chimpanzees
sequenced for each subspecies is indicated.
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(SI Appendix, Fig. S4). The results of these studies largely reca-
pitulated the replication data obtained in primary CD4+ T cells
(Figs. 1 and 3). First, most SIVcpz Envs used the human CD4
more efficiently than any of the chimpanzee CD4 alleles (Fig. 3),
consistent with the universal susceptibility of human CD4+ T cells
to SIVcpz infection. Second, the Env of the promiscuous MT145
strain utilized all CD4 alleles while cell entry of the more re-
stricted MB897 Env was markedly reduced in QQNVT-expressing
cells and nearly completely blocked in QRNVP- and QRKVT-
expressing cells (Fig. 3). Analysis of new CD4 alleles from wild
chimpanzees extended these results and identified R25, R40, and
T68 as the most inhibiting substitutions. All chimpanzee CD4 al-
leles contain a PNGS at residue 32, not found in human CD4,
while those with a threonine at position 68 (T68) contain two
PNGSs. Interestingly, chimpanzee CD4 alleles with a P at position
68 (P68) reduced the infectivity of all SIVcpz Envs, compared with
the human CD4, while chimpanzee CD4 alleles that encoded a
threonine at position 68 (T68) reduced their infectivity even fur-
ther (SI Appendix, Fig. S5A). This inhibition was not dependent
on the baseline infectivity of these SIVcpz Envs, nor on the allelic
context of the P68T substitution (SI Appendix, Fig. S6A), sug-
gesting that the presence of two glycans in the D1 domain is more
protective than the presence of only one.
In contrast to the changes in PNGS numbers, other amino acid
substitutions in the D1 domain affected only a subset of SIVcpz
Envs. For example, the substitution of a glutamine to an arginine
at position 25 (Q25R) reduced cell entry of BF1167, TAN2, and
TAN13 by up to 18-fold but had little effect on the remaining
SIVcpz Envs, except for GAB2, whose infectivity was slightly
enhanced (SI Appendix, Figs. S5B and S6B). Similarly, the sub-
stitution of a glutamine to an arginine at position 40 (Q40R)
reduced MB897, BF1167, TAN2, and TAN13 cell entry more
than 100-fold but did not appear to inhibit any of the other
SIVcpz Envs (SI Appendix, Figs. S5C and S6C). The change from
an asparagine to a lysine at position 52 (N52K) inhibited all
SIVcpz Envs modestly in the context of the QQNVP allele but
had a slight enhancing effect in the context of the QQNVT allele
(SI Appendix, Figs. S5D and S6D). Finally, the change from a
valine to an isoleucine at position 55 (V55I) had no detectable
effect in the context of both the QQNVP and QRNVP alleles (SI
Appendix, Figs. S5E and S6E). Thus, while CD4 polymorphisms
were able to block SIVcpz cell entry, the inhibitory effects were
variable, context-dependent, and strain-specific.
Chimpanzee CD4 Polymorphisms Interfere with Env Binding by
Altering Contact Residues at the CD4–Env Interface. Having identi-
fied protective CD4 alleles, we next sought to examine the breadth
of this protection and the associated mechanism(s). Both R25-
and R40-containing CD4 alleles inhibited primarily SIVcpzPts
strains (Figs. 3 and 4), but CD4 genotyping of 128 chimpanzees
from Gombe National Park identified two SIVcpzPts-infected
individuals that were R25-heterozygous. Since the virus of one
of these individuals (TAN1) has been molecularly cloned (44), we
tested its Env in the CD4 transfection assay (Fig. 4A). This
analysis showed that TAN1, in contrast to the other SIVcpzPts
Envs, was able to utilize the R25 allele (Fig. 4A). Similarly, of five
SIVcpzPtt strains, four were resistant to the R40 inhibition, and all
four were derived from chimpanzees that encoded at least one
R40-containing allele (Fig. 4C). Thus, for both R25 and R40 poly-
morphisms, in vivo adaptation had generated SIVcpz strains that
were capable of utilizing these CD4 variants.
To identify the mechanisms of inhibition mediated by R25 and
R40, we mapped these CD4 residues onto an existing crystal
structure of the human CD4 bound to HIV-1 gp120 (38). We then
searched for Env amino acids that were in close proximity to these
CD4 residues but differed between restricted and permissive
SIVcpz strains (Fig. 4 B and D). For the R25 polymorphism, we
found that Env residue 474 (HXB2 reference sequence number-
ing) was negatively charged or neutral in all viruses that were able
to utilize the RQNVP allele, but positively charged in SIVcpz
strains that were unable to utilize this allele (Fig. 4B). This finding
suggested that the CD4 R25 repulsed positively charged Env
amino acids at position 474, thus destabilizing the Env–CD4 in-
teraction. Since the permissive TAN1 strain encoded a valine at this
position, we mutagenized a restricted Env (TAN2) by replacing
its lysine with a valine (K474V). This single amino acid substitu-
tion was sufficient to render the TAN2 Env infectious for cells
expressing the RQNVP allele without altering its ability to utilize
the QQNVP allele (Fig. 4E). Similarly, residue 455 tended to be
negatively charged in Envs that could use R40-containing CD4 al-
leles, but neutral in Envs that were blocked by this allele (Fig. 4D).
In this instance, the different orientation of the R40 side chain was
incompatible with an interaction with Env residue T283, the contact
residue for CD4 Q40. However, this loss was predicted to be po-
tentially offset by the formation of long-range salt bridges between
CD4 R40 and a negatively charged residue at Env position 455. In
line with this prediction, replacing a threonine at position 455 with
an aspartic acid (T455D) in the restricted MB897 Env was sufficient
to restore its infectivity for QRNVP-expressing cells without altering
its ability to utilize the QQNVP allele (Fig. 4E).
To examine the effect of the T455D mutation in the context of
a replication-competent virus, we introduced this change into the
MB897 infectious molecular clone and tested its infectivity in
CD4+ T cells from a chimpanzee (Chip) that was heterozygous
for the QRNVP and QQNVT alleles (Fig. 1). Remarkably, this
single amino acid substitution rendered MB897 infectious in
cells that were completely refractory to the WT virus (Fig. 4F),
and the same results were obtained in CD4+ T cells from a
chimpanzee that was heterozygous for QRKVT and QQNVT
alleles (SI Appendix, Fig. S7A). Although Env amino acid 455 is
unlikely the only residue impacted by the R40 substitution (the
LB715 Env encodes a T at position 455 but is able to use the
QRNVP allele), it seems clear that changes in the charge of Env/
CD4 contact residues represent one mechanism by which
CD4 polymorphisms prevent Env-mediated cell entry. Of note,
R25 and R40 blocked CD4/Env interaction by different means
since Env mutations that restored infectivity for one of these
CD4 alleles did not restore infectivity for the other (Fig. 4E).
Chimpanzee CD4 Polymorphisms Cause Glycan–Glycan Steric Hindrance.
In contrast to the R25 and R40 alleles, the T68 polymorphism
inhibited all SIVcpz Envs regardless of their baseline infectivity
(Fig. 3). Since T68 creates a PNGS at position N66 in addition to
the N32 that is present in all chimpanzee CD4 alleles, we asked
whether these sites were indeed glycosylated. Immunoprecipitation
of CD4 proteins from cells transfected with human and chim-
panzee (QQNVP and QQNVT) alleles revealed differences in
electrophoretic mobility consistent with glycan occupancy, which
was confirmed by endoglycosidase H treatment (SI Appendix, Fig.
S8). To determine whether these D1 domain glycans interfered
Fig. 3. Chimpanzee CD4 polymorphisms govern SIVcpz Env-mediated cell
entry. The infectivity of pseudoviruses carrying different SIVcpz Envs is
shown for transiently transfected cells expressing human and chimpanzee
CD4 alleles. The infectivity on human CD4-expressing cells is set to 100%.
Bars represent the average of three independent transfections, each per-
formed in triplicate, with standard deviations shown.









with glycans on the various SIVcpz Envs, we modeled their posi-
tion in the crystal structure of the human CD4 bound to HIV-
1 gp120 (38). This analysis identified three glycans in the MB897
Env that were predicted to clash with glycans in the chimpanzee
CD4 protein (Fig. 5A). Env glycan N460 was predicted to clash
with CD4 glycan N32 while Env glycans N295 and N446 were
predicted to clash with CD4 glycan N66, albeit on adjacent Env
protomers. Interestingly, no substantial glycan–glycan clashes were
predicted for the Envs of MT145 and TAN2, both of which were
able to replicate efficiently in CD4+ T cells from QQNVT-
homozygous chimpanzees (Fig. 1D).
To examine whether removal of the clashing glycans in the
MB897 Env would increase its infectivity, we changed the as-
paragine residues at positions 295, 446, and 460 to glutamines
and then tested these mutants, alone and in combination, in the
transient CD4 transfection assay (Fig. 5B). Interestingly, the N460Q
and the triple mutant increased the infectivity of the MB897 Env in
both QQNVP- and QQNVT-expressing cells (Fig. 5B). In contrast,
removal of N295 and/or N446 had little effect in the context of
either allele (Fig. 5B). Introduction of these same mutations into the
MB897 infectious molecular clone were consistent with these re-
sults. Compared with WT MB897, both the N460Q and the triple
mutant grew faster and to higher titers in CD4+ T cells from a
QQNVP/QQNVT-heterozygous chimpanzee (Fig. 5C). The
N460Q mutant also replicated in CD4+ T cells from one, but not
all, QQNVT-homozygous chimpanzees (Fig. 5 D and E) while
N295Q and/or N446Q mutants again had no effect. Thus, removal
of an Env glycan predicted to clash with the conserved N32 in-
creased the infectivity of the MB897 strain, both in transient
transfection and replication studies, albeit not to the level of other
QQNVT-permissive SIVcpz strains, such as MT145. Removal of
the other two glycans failed to restore infectivity, although this was
not due to a fitness cost, since all mutants replicated to the same
extent in human CD4+ T cells (SI Appendix, Fig. S7B). Thus, in
silico modeling of the CD4 and Env glycan shields did not fully
recapitulate the extent of their interactions.
Chimpanzee CD4 Polymorphisms Protect Against SIVs Infecting Old
World Monkeys. To test whether the inhibitory effect of the
chimpanzee CD4 polymorphisms extended to more diverse SIVs,
we cloned env genes from several SIV lineages into expression
vectors, generated pseudoviruses, and tested their functional in-
tegrity in TZM-bl cells. Infectious Envs were then tested for
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Fig. 5. Steric hindrance between CD4- and SIVcpz Env-encoded glycans. (A)
A model of two SIVcpz Envs (Top, MB897; Bottom, MT145) in complex with
the chimpanzee CD4 QQNVT variant (containing both N32 and N66 glycans)
is shown. Env residues are shown in purple, Env glycans in green, and
CD4 glycans in red. (B) Infectivity of WT and mutant MB897 Envs lacking the
indicated glycans in cells expressing different CD4 alleles (parentheses in-
dicate the number of D1 domain glycans). Asterisks denote significant en-
hancement of the mutant Envs relative to the MB897 WT (orange) for that
particular allele. (C–E) Replication of wild-type and mutant MB897 viruses in
CD4+ T cells from one heterozygous chimpanzee encoding QQNVP and
QQNVT alleles (C) and two homozygous chimpanzees encoding the QQNVT




Fig. 4. SIVcpz cell entry is blocked by charged residues at the CD4–Env in-
terface. (A and C) Percentage of cells expressing the indicated CD4 alleles
that are infected by SIVcpz Env-containing pseudoviruses. Points connected
by lines represent paired averages of three independent experiments, each
performed in triplicate. The parentheses indicate the CD4 genotype (amino
acid at positions 25 in A and position 40 in C) of the naturally infected
chimpanzee from which the respective SIVcpz Env was derived. (B and D)
Modeling of chimpanzee CD4 residues 25 (B) and 40 (D) onto the crystal
structure of the HIV-1 gp120 (yellow) bound to human CD4 (green). Poly-
morphic CD4 residues are shown in dark blue (Q) and red (R), respectively.
Env residues in proximity to these polymorphic sites are highlighted. Partial
Env protein alignments for the tested SIVcpz strains are shown, with the
residue predicted to interact with the polymorphic CD4 residue high-
lighted (blue for Envs that can use both Q and R residues, red for Envs that
are inhibited by the R residue). (E ) Infectivity of WT (MB897, TAN2) and
mutant (MB897 T455D, TAN2 K474V) SIVcpz Envs on cells expressing the
indicated chimpanzee CD4 alleles. Circles represent average infectivity
values from three independent experiments, each performed in triplicate,
with mean and standard deviation shown. Significant differences are in-
dicated (**P < 0.01, unpaired t test). (F ) Replication potential of wild-type
(wt) and mutant (T455D) MB897 and wild-type MT145 in chimpanzee CD4+
T cells heterozygous for QRNVP and QQNVT alleles. Viral replication was
monitored in culture supernatants by determining reverse transcriptase
(RT) activity.
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were further analyzed. Using the transient CD4 transfection assay,
we identified nine Envs from SIVs infecting mustached monkeys
(Cercopithecus cephus), l’Hoest’s monkeys (Cercopithecus lhoesti),
western red colobus (Procolobus badius), red-tailed monkeys
(Cercopithecus ascanius), sooty mangabeys (Cercocebus atys), and
African green monkeys (Chlorocebus tantalus) that mediated entry
into cells expressing the human CD4 (Fig. 6A). However, when
these same Envs were tested in cells expressing the chimpanzee
QQNVP allele, the great majority exhibited markedly reduced
infectivity, with some of them inhibited even more in cells expressing
the chimpanzee QQNVT allele (SI Appendix, Fig. S6F). To examine
possible mechanisms, we mutagenized the conserved N32 glycan
in both the QQNVP and QQNVT alleles. Changing the aspara-
gine at position 32 to a glutamine (N32Q) in the QQNVP allele
enhanced the infectivity of most SIV Envs, suggesting that their
inhibition was primarily glycan-mediated (SI Appendix, Fig. S6F).
However, the same mutation in the QQNVT allele did not restore
Env infectivity, suggesting that one glycan in the D1 domain is
sufficient to exert inhibition (Fig. 6B and SI Appendix, Fig. S6F).
For six SIV Envs that retained infectivity for the chimpanzee
QQNVP allele, we also tested the remaining CD4 polymorphisms
(Fig. 6C). Both the N52K and V55I polymorphisms inhibited Envs
of the SIVsmm lineage but had little effect on the other SIV Envs,
except for SIVagm, which was enhanced by the K52 substitution
(SI Appendix, Fig. S6G). Since the African green monkey CD4
encodes an R at position 52, this substitution likely generated a
chimpanzee CD4 allele that resembled the cognate SIVagm re-
ceptor more closely. The R25 substitution inhibited one SIVagm
and one SIVsmm Env, but none of the other SIV Envs (SI Ap-
pendix, Fig. S6G). The most pronounced protective effect was
again observed for the R40 substitution, which reduced cell entry
of all SIV Envs by ∼10-fold, except for the Env of SIVasc (SI Ap-
pendix, Fig. S6G). Thus, like for SIVcpz strains, CD4 polymorphism-
mediated inhibition of SIV cell entry was strain-specific and context-
dependent.
CD4 Receptor Diversity Protects Wild Chimpanzees from SIVcpz
Infection. Finally, we asked whether the various chimpanzee
CD4 alleles influenced SIVcpz acquisition in vivo. To address
this, we selected chimpanzee communities at two field sites
where CD4 diversity could be analyzed in the context of high
SIVcpz prevalence rates (SI Appendix, Table S3). One included
Gombe National Park, where members of the Mitumba, Kase-
kela, and Kalande communities have been monitored for SIVcpz
for two decades and where the negative impact of this infection
on chimpanzee health was first demonstrated (27, 28). The other
included the Lobéké (LB) and Mambélé (MB) area in south-
eastern Cameroon where chimpanzees harbor the closest rela-
tives of HIV-1 group M at high prevalence rates (22). Using
logistic regression to examine the effect of CD4 substitutions on
SIVcpz infection relative to the ancestral CD4 allele, we found a
suggestion of a protective effect for the R25 polymorphism in the
Gombe population although this did not reach statistical signif-
icance (Fig. 7A). The 70 chimpanzees from the Lobéké (LB) and
Mambélé (MB) area lacked the R25 polymorphism but encoded
CD4 alleles with other substitutions in exon 2 and exon 3. When
these were analyzed, none of them reached statistical significance
although there was a trend for R40 and K52 to be associated with
lower, and for I55 to be associated with higher, SIVcpz infection
rates (Fig. 7B). Surprisingly, the T68 substitution did not appear to
have a detectable effect. However, since only 4 of 46 individuals
encoded T68 in the absence of K52, the impact of these two
substitutions could not be differentiated. Interestingly, when the
LB/MB data were analyzed at the whole exon level, the KVT
allele was associated with 3.4-fold lower odds of being infected
(P = 0.03, 95% CI: 1.07- to 10.8-fold) (Fig. 7). These data thus
suggest that K52 (alone or in combination with T68) and, possibly,
also R25 protect wild chimpanzees against infection by locally
circulating SIVcpz strains although definitive conclusions must
await more extensive sampling of wild populations.
Discussion
Pathogenic SIVs have long been assumed to be the driving force
behind the positive selection of primate CD4, but direct evidence
has been lacking (39, 40). Here, we show that wild chimpanzees
encode nine different CD4 variants, all of which are the result of
nonsynonymous SNPs in the D1 domain that binds the HIV/SIV
Env trimer (Figs. 1 and 2). Testing their impact on virus in-
fection, we found that these polymorphisms inhibited cell entry
of SIVcpz, as well as more distantly related SIVs, albeit in a
strain-specific and context-dependent manner (Figs. 3 and 7).
The most striking effects were seen for amino acid substitutions
at positions 25, 40, and 68 of the mature CD4 protein in codons
not previously identified to be under positive selection (39, 40).
In silico modeling and site-directed mutagenesis identified
charge changes at the Env/CD4 interface (Fig. 4) as well as
clashes between Env- and CD4-encoded glycans (Fig. 6) as
mechanisms of cell entry inhibition. The finding of polymor-
phisms in the chimpanzee CD4 that alter its function as a virus
receptor, but do not appear to interfere with its MHC class II
binding ability, strongly suggest that they evolved in response to
SIV-mediated selection.
Although SIVcpz is pathogenic in chimpanzees (26–28), it is
unlikely that it is the only SIV that has exerted pressure on the
chimpanzee CD4 protein. P. t. verus and P. t. ellioti do not harbor
SIVcpz, which suggested a more recent introduction of this virus,
after the split of these subspecies from P. t. troglodytes and P. t.
schweinfurthii. Indeed, the structure of the SIVcpz genome rep-
resents a complex mosaic, which resulted from the cross-species
transmission and recombination of SIV lineages infecting red-
capped mangabeys (Cercocebus torquatus) and certain Cercopi-
thecus monkey species (10). Since the ranges of these species
overlap that of P. t. troglodytes apes, it seemed likely that SIVcpz
A
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Fig. 6. Chimpanzee CD4 polymorphisms protect against monkey SIVs. (A)
Percent infectivity of Env-carrying pseudoviruses from diverse SIV lineages
(color-coded) of cells expressing the indicated CD4 alleles (parentheses in-
dicate the number of D1 domain PNGSs). Bars represent the average of three
independent experiments, each performed in triplicate. Infectivity values are
shown relative to the human CD4, which was set to 100%. Asterisks indicate
statistically significant differences between the chimpanzee QQNVP and the
human CD4, as well as between the chimpanzee QQNVP and QQNVT alleles
(SI Appendix, Fig. S6). (B) Effect of the N32 glycan on SIV Env infectivity.
Average infectivity values are shown for each Env tested against CD4 alleles
with intact or mutated N32. Solid lines indicate statistical significance (SI
Appendix, Fig. S6). (C) Effect of CD4 polymorphisms on SIV Env infectivity.
Percent infectivity values are compared between chimpanzee CD4 allele
pairs that differ at one polymorphic site (highlighted in red). Solid lines in-
dicate statistical significance (SI Appendix, Fig. S6).









first emerged in west central Africa and subsequently spread
eastward (16). However, the fact that P. t. ellioti, P. t. troglodytes,
and P. t. schweinfurthii share several CD4 alleles indicates that
CD4 diversification preceded their divergence (Fig. 2). Thus, ei-
ther current-day SIVcpz is much older than previously thought
and selected CD4 variants in ancestral chimpanzees before be-
coming extinct in P. t. verus and P. t. ellioti, or chimpanzees have
been episodically infected with different SIVs throughout their
evolutionary history, which placed pressure on their CD4. Still
another possibility is that some, or all, of the CD4 polymorphisms
were selected by unrelated pathogen(s) (53, 54). However, others
have independently implicated an ancient SIV infection to explain
the skewed MHC class I repertoires of chimpanzees and bonobos,
which include allotypes that resemble AIDS-protective human
HLA alleles (55). Thus, there are several lines of evidence to
suggest that different SIVs, both extant and extinct, have shaped
the evolution of the chimpanzee CD4.
The finding of only a single CD4 allele in western chimpanzees
is intriguing. This could indicate that the selection pressure that
maintains CD4 diversity in the other subspecies has been re-
moved although these apes are almost certainly exposed to a
similar variety of SIVs from various sympatric monkey species.
Alternatively, exposure to new SIV(s) as the ancestors of P. t.
verus migrated westward may have led to a selective sweep fixing
the one CD4 allele although there is no obvious trough of ge-
netic diversity surrounding the CD4 locus (SI Appendix, Fig.
S10). This particular allele is now extremely rare among the
other three subspecies, but its fixation in the western subspecies,
either by selection or drift, suggests that it was more common in
the past.
Current data indicate that the SIV/HIV Env trimer must en-
gage at least two different CD4 molecules before it can trigger
fusion and cell entry (56–58). Although the regulation of CD4
expression in heterozygous chimpanzees is unknown, it is likely
that CD4+ T cells express both CD4 alleles (59–61). If two dif-
ferent CD4 variants are expressed on the same target cell, then
multiple permutations of Env trimer binding are possible.
Depending on the stoichiometry and kinetics of engagement,
interaction of Env protomers with CD4 molecules that vary in
their binding affinities may result in less efficient cell entry than
interaction with CD4 molecules that do not exhibit this difference.
It is also possible that in vivo adaptation of a virus to one set of
CD4 alleles decreases its fitness to infect chimpanzees that encode
a different set of CD4 alleles. For example, adaptation of SIVcpz
strains to CD4 alleles that encode two D1 domain glycans through
modification of their Env glycan shield may render them more
vulnerable to host immune responses. The loss of Env glycan shield-
ing, as seen in the promiscuous MT145 strain (Fig. 5A), is known to
generate epitopes that are targeted by strain-specific neutralizing an-
tibodies, which select for viral escape variants in which the glycan
holes are filled (62). Thus, the requirement to interact with different
CD4 alleles may curb SIVcpz transmission and/or reduce viral repli-
cation in infected individuals. Interestingly, of three captive chim-
panzees that were infected with the same SIVcpz strain (ANT)
at the same time over 20 y ago, only the two that were homo-
zygous for the QQNVT allele developed high viral loads and
progressed to AIDS (30, 63, 64). The third individual, who is
heterozygous for QQNVT and QQNVP alleles, exhibited much
lower viral loads and has remained healthy (SI Appendix, Table
S4). These findings suggest that CD4 variants are maintained in
wild chimpanzee populations because they confer a heterozygote
advantage.
One CD4 polymorphism that potently inhibits SIVcpzPts
strains in vitro is the R25 substitution (Fig. 3). Despite screening
over 500 chimpanzees, this polymorphism was found only in
chimpanzees from Gombe National Park. The limited geo-
graphic distribution suggests that the RQNVP allele may have
emerged relatively more recently although definitive conclusions
require testing of additional communities. Since there was a
trend for the RQNVP allele to be associated with lower SIVcpz
infection rates (Fig. 7), we examined its distribution among the
three Gombe communities. Interestingly, of 23 CD4-genotyped
Kalande chimpanzees, 11 of whom were SIVcpz-positive, none
carried the RQNVP allele. In contrast, of 75 and 30 Kasekela and
Mitumba chimpanzees, 20% and 10% of whom were infected,
respectively, 23 and 3 carried at least one RQNVP allele. Thus,
one reason for the higher SIVcpz prevalence in the Kalande
community, which has been linked to its catastrophic population
decline (28), may be the absence of the protective RQNVP allele.
Although it is unclear why the distribution of the RQNVP allele is
so different between the otherwise interconnected Gombe com-
munities, it will be important to determine whether its frequency
can explain differences in SIVcpzPts prevalence rates that are
particularly pronounced among P. t. schweinfurthii communities in
the easternmost part of their range (21).
Humans acquired the ape precursors of HIV-1 by cross-
species transmission on four independent occasions, resulting in
groups M, N, O, and P (16). In contrast, SIVcpz appears to have
arisen only once, despite frequent exposure of chimpanzees to
SIVs (31). Here, we show that receptor glycosylation serves as a
potent barrier to SIV cell entry. Both conserved (N32) and
variable (N66) D1 domain glycans were shown to inhibit not only
SIVcpz, but also other SIV strains (Fig. 6). While many addi-
tional SIV lineages remain to be analyzed, our data indicate that
steric hindrance between cell entry receptor-encoded and virus
surface protein-encoded glycans represents a mechanism of an-
tiviral protection that has not previously been described. Indeed,
glycosylation of the CD4 receptor is common among primates
where PNGS are found at variable positions in the D1 domain
(SI Appendix, Table S5). Moreover, all of these appear to be
under positive selection within the primate lineage (SI Ap-
pendix, Fig. S9). Humans lack D1 domain glycans, which may
explain their relative susceptibility to SIVcpz, SIVgor, and
SIVsmm infections, which have crossed the species barrier on
at least 12 occasions (16). Conversely, the presence of glycans
on the chimpanzee CD4 must be one reason why chimpanzees
are largely resistant to experimental HIV-1 infection. It will
be interesting to examine the evolution of the Env glycan
shield in HIV-1 strains that were able to establish a productive
infection in chimpanzees after multiple rounds of in vivo ad-
aptation (65).
The discovery of CD4-mediated protection has practical im-
plications for AIDS vaccine development. We recently discov-
ered that a subset of SIVcpz strains share unexpected antigenic
cross-reactivity with HIV-1 in the functionally important V1V2
region of the Env trimer apex (45). This finding raised the ques-
tion whether SIVcpz Envs, which are otherwise antigenically
highly divergent from HIV-1, could serve to immunofocus B cell
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Fig. 7. Effect of CD4 polymorphisms on SIVcpz infection rates in wild
chimpanzees. A logistic regression was used to estimate the effects of
CD4 polymorphisms on SIVcpz infection in wild-living chimpanzees from (A)
Gombe and (B) Lobéké/Mambélé. Dots indicate the estimated effect of the
presence of the given residue (Left) or allele (Right) relative to the ancestral
state, with horizontal lines indicating the 95% confidence intervals (substi-
tutions/alleles that could not be estimated by the model due to insufficient
variation in the population are not shown). Dashed vertical lines mark a fold
change of 1, indicating no predicted change in SIVcpz infection rate relative
to the ancestral state.
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modified Env of the SIVcpz strain MT145 was recently shown to
display selective binding to HIV-1 V2-apex broadly neutralizing
antibodies (bNabs) and their precursors, and to prime heterolo-
gous (tier 2) neutralizing antibody responses in V2 apex bNab
precursor antibody-expressing knock-in mice (66). MT145 is the
only SIVcpz strain that was able to replicate in CD4+ T cells of all
chimpanzees (Fig. 1), at least in part because it lacks Env glycans
predicted to clash with N32 and N66 in the chimpanzee CD4 (Fig.
5A). Indeed, cryo-EM analysis of the MT145 Env trimer revealed
that its structure is remarkably similar to that of the HIV-1 Env,
except for a shift in the arrangement of its glycans (66). It thus
appears that MT145 has evolved to accommodate the chimpan-
zee CD4-mediated cell entry block by rearranging its Env glycan
shield. However, the absence of the N460 glycan exposes a long
V5 loop (Fig. 5A), which has the potential to induce unwanted
(off-target) antibody responses. Since there are other SIVcpz Envs
that contain the cross-reactive V2 apex epitope but lack the long
unshielded V5 loop (45), they may be more suitable components
of an immunofocusing strategy to elicit V2 apex bNab responses.
As vaccines including SIVcpz Env immunogens are moving to-
ward human clinical testing, understanding the impact of chim-
panzee CD4 diversification on their structure and function will
inform AIDS immunogen design.
Methods
Vectors. The construction and biological characterization of the SIVcpz IMCs
have previously been reported (21, 44–47). Insertion of a GFP-internal ri-
bosome entry site (IRES) cassette between the env and nef genes of the
MB897 IMC generated a replication-competent SIVcpz-GFP reporter virus,
which was further modified by inserting a frameshift at position 6,493 in the
env gene for pseudotyping studies. WT or codon-optimized SIVcpz and SIV
env genes were cloned into pcDNA3.1. Full-length chimpanzee and human
CD4 coding sequences, as well as the chimpanzee CCR5 gene, were cloned
into pMSCVpuro (Takara Bio Inc.).
Virus Stocks. Viral stocks were generated by transfecting of 293T cells with
SIVcpz IMCs and by testing the culture supernatants for infectivity on TZM-bl
cells. Pseudovirus stocks were generated by cotransfecting the MB897ΔEnv-
GFP backbone with WT or codon-optimized SIVcpz and SIV Env expression
plasmids and also titered on TZM-bl cells. The replication-competent MB897-
GFP IMC was used for VSV-G complementation studies.
CD4+ T Cell Cultures. Blood samples were obtained from captive chim-
panzees housed at the Yerkes National Primate Research Center, the
Southwest National Primate Research Center, and the New Iberia Re-
search Center during their annual health examination. Only leftover material
was used, which was approved by the respective Institutional Animal Care and
Use Committees. Human blood was purchased (ZenBio, Inc). Chimpanzee and
human CD4+ T cells were isolated, activated, and infected overnight at a
multiplicity of infection (MOI) of 0.1 as described (44, 67). Virus replication
was assessed by monitoring reverse transcriptase activity (Sigma-Aldrich)
or the presence of p24 core protein (AlphaLISA Detection Kit; Perkin-Elmer)
in culture supernatants.
CD4 and CCR5 Genotyping. To determine the CD4 and CCR5 genotype of
captive chimpanzees, total RNA was extracted from activated CD4+ T cells
and reverse transcribed using SuperScript III (Thermo Fisher) gene-specific
primers. To preclude PCR artifacts, cDNA was endpoint diluted (48) to am-
plify single mRNA templates (see SI Appendix, SI Materials and Methods for
primer sequences and amplification conditions). Multiple amplicons were
MiSeq sequenced to determine the CCR5 and CD4 genotype (SI Appendix,
Table S2). To CD4 genotype wild chimpanzee populations, samples were
selected from existing specimen banks (4, 21, 22, 27, 28, 49, 50) based on
geographic origin, subspecies association, SIVcpz infection status, and host
mitochondrial and microsatellite information, as well as sample availability
and quality (SI Appendix, Tables S3 and S6 for available sample information).
CD4 exon 2 (247 bp) and exon 3 (222 bp) regions were amplified using
primers in adjacent introns (SI Appendix, SI Materials and Methods).
Amplicons were MiSeq sequenced without fragmentation to ensure linkage
of variable sites (68, 69). Homozygous loci were amplified at least eight
times to exclude allelic dropout (SI Appendix, Table S3).
Transient CD4 Transfection Assay. Todetermine the ability of SIVcpz and SIV Envs
to utilize different CD4 alleles for cell entry, we developed a single round
infection assay. Briefly, 293T cells were cotransfected with human and chim-
panzee CD4 and chimpanzee CCR5 expression plasmids, cultured for 48 h, and
then plated in 96-well plates at a density of 2 × 104 cells per well. After 24 h,
transfected cells were infected with 5,000 infectious units (IUs) of SIV Env
bearing pseudovirus by spinoculation, cultured for 48 h, and then analyzed
for GFP expression by flow cytometry (SI Appendix, Fig. S4). CD4 and
CCR5 expression levels were determined at the time of infection using
receptor-specific antibodies, and the percentage of infected cells was
calculated by dividing the number of GFP-expressing cells by the number
of CD4- and CCR5-expressing cells for each transfected cell population.
All Envs were analyzed in triplicate on three independent occasions.
Modeling Glycosylated SIVcpz Env Trimer and CD4. To obtain models of SIVcpz
trimers and CD4 variants, the structure of HIV-1 clade G ×1193.c1 SOSIP.665 (PDB
ID code 5FYJ) protein (70) and the human CD4 (PDB ID code 1GC1) protein (38)
were used as templates in SwissModel (71). N-linked Man-5 glycans were added
to both SIVcpz trimer and CD4 models in silico using the in-house program
Glycosylator at all possible glycosylation sequons. Complexes of modeled glyco-
sylated CD4 and SIVcpz trimers were built by structural alignment of gp120 from
1GC1 to the corresponding residues in the trimeric SIVcpz gp120. Gycan–glycan
spatial overlaps were evaluated by visual inspection of multiple glycan rotamers.
Statistical Analyses. To assess the effects of CD4 polymorphisms on SIVcpz-
and SIV Env-mediated cell entry in vitro, we used a hierarchical Bayesian
model (SI Appendix). For each pair of CD4 alleles, the fold change in in-
fectivity for the various Envs, as well as an overall effect estimate, was
modeled using Stan (72). To assess the effects of CD4 polymorphisms on
SIVcpz infection in vivo, we selected two different populations of eastern
(Gombe) and central (Lobéké/Mambélé area) chimpanzees that were in-
fected at high SIVcpz prevalence rates. We then performed a logistic re-
gression of SIVcpz status on sets of indicator variables that specified whether
a chimpanzee possessed a given CD4 substitution or allelic variant, while
setting the ancestral state as the background. This analysis tested whether
the presence of a given substitution or allele within a community positively
or negatively associated with SIVcpz infection relative to the ancestral (g)
QQNVP genotype although the model did not account for zygosity or syn-
ergistic effects between polymorphisms.
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